$25.73
▼ -1.9% Today
as of Sep 4, 16:56 ET
Last 30 days
Recent Press Releases & News
Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)?
Global DLL3 Targeted Therapies Market 2026-2030: Profiles Amgen, Zai Lab, Boehringer Ingelheim and Phanes Therapeutics
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Overview
52-week range
$16
$35
52% of range
Avg surprise (last 3)
+10.2%
Avg reaction (last 2)
-1.6%
50% positive
Latest IV / EM
118%
EM ±18.4% · $25 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.05 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $-0.46 | $-0.58 | +20.7% | -2.2% | -5.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.03 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.37 | $-0.37 | 0.0% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.45 | $-0.50 | +10.0% | — | +2.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.04 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.08 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.05 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.07 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.13 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.05 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $106M | $100M | — | $116M | $110M | $106M | — | $102M |
| Cost of revenue | $48M | $38M | — | $47M | $43M | $38M | — | $37M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-76M | $-69M | — | $-49M | $-55M | $-56M | — | $-68M |
| Net income | $-51M | $-51M | — | $-36M | $-41M | $-48M | — | $-42M |
| EPS (diluted) | $-0.05 | $-0.05 | — | $-0.03 | $-0.04 | $-0.04 | — | $-0.04 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $608M | $651M | $680M | $717M | $732M | $757M | $450M | $616M |
| Inventory | $91M | $86M | $75M | $67M | $62M | $53M | $40M | $40M |
| Total current assets | $914M | $945M | $1.02B | $1.03B | $1.03B | $1.04B | $1.05B | $861M |
| Total assets | $1.07B | $1.10B | $1.17B | $1.16B | $1.16B | $1.17B | $1.19B | $985M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $468M | $434M | $457M | $399M | $372M | $363M | $345M | $318M |
| Total equity | $607M | $662M | $716M | $760M | $792M | $811M | $841M | $668M |